Andere talen Ocular Therapeutix, Inc.

Aandelen

OCUL

US67576A1007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6 ^USD	-1,64%		-4,61%	+34,53%

16/05	Transcript : Ocular Therapeutix, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
07/05	Ocular Therapeutix, Inc. meldt winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05
Ocular Therapeutix: Q1 Earnings Snapshot	07/05
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	07/05
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Ocular Therapeutix™ Reports First Quarter 2024 Results	07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05
Ocular Therapeutix to Present at Two Ophthalmology Meetings, May 4-9, 2024	06/05
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences	06/05
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024	03/05
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024	01/05
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19/04
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	18/04
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	18/04
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	18/04
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy	18/04
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18/04
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	16/04
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders	16/04
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	15/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ocular Therapeutix, Inc.

Aandelen

OCUL

US67576A1007

Andere talen

Filters